active specific immunotherapy

active specific immunotherapy

a therapy that attempts to stimulate specific antitumor responses with tumor-associated antigens as the immunizing materials.
Mentioned in ?
References in periodicals archive ?
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.
In the agreement, Vaccinogen obtained exclusive license to OncoVAX(R) Active Specific Immunotherapy as well as an important component of the product TICE BCG.
The study is designed to test active specific immunotherapy with BLP25 vaccine as a treatment for patients who have recurrent disease following radical prostatectomy for prostate cancer.
The presentation, entitled Active Specific Immunotherapy of Adenocarcinomas Using Cancer-Associated Antigens was made at the Second Annual New Advances in Vaccine Technologies & Applications conference in Bethesda, Md.
MUCI Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIb-IV non-small cell lung cancer (NSCLC)," the authors concluded that, "the vaccine was well tolerated and showed important signs of immunogenicity.
The company is refining its technology in the areas of active specific immunotherapy (THERATOPE R therapeutic vaccine) anti-idiotype induction therapy (OVAREX TM antibody kits), radioimmunoimaging (Tru-Scint R compounds), as well as cancer diagnostic kits (TRUQUANT R radioimmunoassays).
The paper focuses on the concept that THERATOPE(R) vaccine's synthetic carbohydrate antigen, Sialyl-Tn (STn), "is an ideal candidate for Active Specific Immunotherapy (ASI)," and that, "ASI is a promising approach to treating cancer.
In parallel to the development of peptide-based products for active specific immunotherapy for cancer, Biomira is also developing a carbohydrate based vaccine which will enter Phase III clinical trials in 1997.
It is refining its technology in the areas of active specific immunotherapy (THERATOPE(R)), radioimmunoimaging (Tru-Scint(R)) and radioimmunotherapy, as well as cancer diagnostic kits (TRUQUANT(R)).
9 million non-cash item relating to Bioalta's decision to exercise its rights to acquire 850,000 common shares of Biomira in lieu of all future royalties on products incorporating Biomira's active specific immunotherapy (ASI) technology - its therapeutic vaccine technology.
The study, published in the February issue of the Journal of Clinical Oncology under the title "Increased Effectiveness of Interferon Alpha-2B Following Active Specific Immunotherapy for Melanoma," was conducted by Malcolm S.
Biomira applies its innovative technology in the areas of active specific immunotherapy (ASI), radioimmunoimaging and radioimmunotherapy.